Clinical Trial Update: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) [Phase 4]

View source ↗

Summary

Phase 4 trial updating all-cause mortality and cardiovascular outcomes in CKD patients on dialysis or not, comparing Mircera to reference ESAs; study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Renal Anemia

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)
• erythropoietin stimulating agents (ESAs)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Chronic Renal Anemia | Phase 4 | Status: COMPLETED | Results posted: 2018-08-15